AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21736780 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplemented with antioxidants (Groups B2 and C2)
Number of subjects: 254
Study 19135997 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track program
Number of subjects: 156
Study 19135997 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 156
Study 19135997 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid administration greater than restriction limits
Number of subjects: 156
Study 19135997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfunctioning epidural analgesia
Number of subjects: 156
Study 17693690 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate (LC) diet
Number of subjects: 1
Study 17693690 — intervention group
Group type: COMPARATOR
Intervention: Grain-Based (GB) diet
Number of subjects: 1
Study 14551140 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg IDEC‐131/E6040
Number of subjects: 20
Study 14551140 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg IDEC‐131/E6040
Number of subjects: 20
Study 14551140 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg IDEC‐131/E6040
Number of subjects: 20
Study 14551140 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg IDEC‐131/E6040
Number of subjects: 20
Study 14551140 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 11382722 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with abciximab
Number of subjects: 2394
Study 9458300 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse colon interposition (TCI)
Number of subjects: 133
Study 9458300 — intervention group
Group type: COMPARATOR
Intervention: Roux en Y anastomosis (R-Y anastomosis)
Number of subjects: 133
Study 8023659 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar epidural administration of 50 micrograms sufentanil
Number of subjects: 30
Study 8023659 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural administration of 50 micrograms sufentanil
Number of subjects: 30
Study 8023659 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly defined)
Number of subjects: 30
Study 8023659 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar group with 75 micrograms sufentanil
Number of subjects: 30
Study 8023659 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic group with 75 micrograms sufentanil
Number of subjects: 30
Study 31829457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic navigation device
Number of subjects: 32
Study 31829457 — intervention group
Group type: COMPARATOR
Intervention: Freehand method
Number of subjects: 32
Study 31198939 — intervention group
Group type: EXPERIMENTAL
Intervention: XAP + probiotics (2,000 U xylanase + 200 U amylase + 4,000 U protease/kg diet + 75,000 CFU/g of Bacillus spp.)
Number of subjects: 48
Study 31198939 — intervention group
Group type: EXPERIMENTAL
Intervention: XAP (2,000 U xylanase + 200 U amylase + 4,000 U protease/kg diet)
Number of subjects: 48
Study 31198939 — intervention group
Group type: EXPERIMENTAL
Intervention: XAP + probiotics
Number of subjects: 48
Study 31198939 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplements)
Number of subjects: 48
Study 31198939 — intervention group
Group type: EXPERIMENTAL
Intervention: XAP
Number of subjects: 48
Study 25346391 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal and social rhythm therapy (IPSRT)
Number of subjects: 100
Study 25346391 — intervention group
Group type: COMPARATOR
Intervention: Specialist supportive care (SSC)
Number of subjects: 100
Study 23587564 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg daily
Number of subjects: 1617
Study 23587564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1617
Study 18478229 — intervention group
Group type: EXPERIMENTAL
Intervention: Open nidus resection guided by a hand‐held gamma probe
Number of subjects: 53
Study 18478229 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 53
Study 17558358 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper extremity use in hemiparetic subjects
Number of subjects: 34
Study 17558358 — intervention group
Group type: COMPARATOR
Intervention: Upper extremity use in healthy control subjects
Number of subjects: 34
Study 17558358 — intervention group
Group type: EXPERIMENTAL
Intervention: Impairment measures related to upper extremity use
Number of subjects: 34
Study 16163159 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation
Number of subjects: 0
Study 16163159 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Number of subjects: 0
Study 16163159 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 0
Study 11981152 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone (0.091% wt/vol)
Number of subjects: 70
Study 11981152 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with epinephrine 1:300,000 (66.7 microg)
Number of subjects: 70
Study 11981152 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with epinephrine
Number of subjects: 70
Study 9857856 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg imidapril
Number of subjects: 244
Study 9857856 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg imidapril
Number of subjects: 244
Study 9857856 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg imidapril
Number of subjects: 244
Study 9857856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 9857856 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of imidapril
Number of subjects: 244
Study 8848531 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 16
Study 8848531 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (2 mg)
Number of subjects: 16
Study 8848531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2227631 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (NOR)
Number of subjects: 59
Study 2227631 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole (TMP/SMX)
Number of subjects: 59
Study 472338 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin pretreatment
Number of subjects: 0
Study 472338 — intervention group
Group type: COMPARATOR
Intervention: PGE2 infusion
Number of subjects: 0
Study 31804890 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (AZ) 500 mg/day
Number of subjects: 10
Study 31804890 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study 30238964 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachers' SEL Belief Scale
Number of subjects: 432
Study 28206704 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks (Q2W), increased to 150 mg Q2W at Week 12 if Week 8 LDL-C was ≥70 mg/dL
Number of subjects: 720
Study 28206704 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg daily
Number of subjects: 720
Study 28206704 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab and Ezetimibe (both groups)
Number of subjects: 720
Study 28206704 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 720
Study 25312605 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation programme (four-week home-based)
Number of subjects: 15
Study 23150188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (EGB 761) 60 mg twice daily
Number of subjects: 166
Study 23150188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 21050797 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological technique
Number of subjects: 15
Study 21050797 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique with addition of a transverse directed force
Number of subjects: 15
Study 19887683 — intervention group
Group type: EXPERIMENTAL
Intervention: Remineralizing cream containing casein phosphopeptide-amorphous calcium phosphate
Number of subjects: 45
Study 19887683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 17448130 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin alone
Number of subjects: 800
Study 17448130 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Rosiglitazone
Number of subjects: 800
Study 17448130 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Intensive Lifestyle Intervention
Number of subjects: 800
Study 15343602 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Doppler analysis
Number of subjects: 74
Study 15343602 — intervention group
Group type: EXPERIMENTAL
Intervention: Color spectral Doppler parameters
Number of subjects: 74
Study 15343602 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest PSV
Number of subjects: 74
Study 15343602 — intervention group
Group type: EXPERIMENTAL
Intervention: PSV
Number of subjects: 74
Study 15343602 — intervention group
Group type: EXPERIMENTAL
Intervention: Median relative color
Number of subjects: 74
Study 15343602 — intervention group
Group type: COMPARATOR
Intervention: 3D color power angiography parameters
Number of subjects: 74
Study 12243825 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF mouthwashes (37.5 microg GM-CSF, 4 times daily)
Number of subjects: 40
Study 12243825 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate mouthwashes (1.0 g sucralfate, 4 times daily)
Number of subjects: 40
Study 9852907 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 15 mumol/L
Number of subjects: 328
Study 9852907 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 50 mumol/L
Number of subjects: 328
Study 9852907 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 100 mumol/L
Number of subjects: 328
Study 9852907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 7537722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziehl‐Neelsen staining method
Number of subjects: 306
Study 7537722 — intervention group
Group type: COMPARATOR
Intervention: Cold staining method
Number of subjects: 306
Study 2913914 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.43 micrograms/d)
Number of subjects: 86
Study 2913914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 30640483 — intervention group
Group type: EXPERIMENTAL
Intervention: DADEE program (9 weekly educational and practical sessions plus home-based challenges)
Number of subjects: 153
Study 30640483 — intervention group
Group type: EXPERIMENTAL
Intervention: DADEE program
Number of subjects: 153
Study 30640483 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 153
Study 27923444 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted lifestyle intervention (seven group sessions on healthy diet and physical activity)
Number of subjects: 96
Study 27923444 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted lifestyle intervention
Number of subjects: 96
Study 27923444 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 96
Study 25838092 — intervention group
Group type: EXPERIMENTAL
Intervention: OIT with Cry j1-galactomannan conjugate
Number of subjects: 47
Study 25838092 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OIT)
Number of subjects: 47
Study 24163189 — intervention group
Group type: EXPERIMENTAL
Intervention: 4,250 IU/day of parnaparin
Number of subjects: 258
Study 24163189 — intervention group
Group type: COMPARATOR
Intervention: 6,400 IU/day of parnaparin
Number of subjects: 258
Study 21083590 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg for 2 weeks
Number of subjects: 805
Study 21083590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 805
Study 19185245 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoilluminator-assisted group (transillumination technique)
Number of subjects: 33
Study 19185245 — intervention group
Group type: COMPARATOR
Intervention: Control group (transscleral fixation without transillumination)
Number of subjects: 33
Study 20084725 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (cisplatin 80 mg/m2 on day 1 and Gemcitabine 1250 mg/m2 on days 1 and 8, every 3 weeks) followed by radiotherapy (60 Gy/30 fractions/6 weeks)
Number of subjects: 69
Study 20084725 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (60 Gy/30 fractions/6 weeks)
Number of subjects: 69
Study 15955041 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine patients without aura
Number of subjects: 72
Study 15955041 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine patients who took a triptan within 3 days prior to investigation
Number of subjects: 72
Study 15955041 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study 12117292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose diacetate
Number of subjects: 10
Study 12117292 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulfone
Number of subjects: 10
Study 12117292 — intervention group
Group type: COMPARATOR
Intervention: EVAL
Number of subjects: 10
Study 9669077 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylocaine (lidocaine) spray
Number of subjects: 82
Study 9669077 — intervention group
Group type: COMPARATOR
Intervention: Normal saline spray
Number of subjects: 82
Study 9669077 — intervention group
Group type: COMPARATOR
Intervention: No spray
Number of subjects: 82
Study 7641121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenormin (100 mg once daily)
Number of subjects: 23
Study 7641121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenolol (100 mg once daily)
Number of subjects: 23
Study 2650646 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium warfarin
Number of subjects: 194
Study 2650646 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 194
Study 2650646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 742832 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum bilirubin
Number of subjects: 155
Study 742832 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated aminotransferases
Number of subjects: 155
Study 742832 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated alkaline phosphatase
Number of subjects: 155
Study 742832 — intervention group
Group type: COMPARATOR
Intervention: Delayed surgery
Number of subjects: 155
Study 742832 — intervention group
Group type: COMPARATOR
Intervention: Early surgery
Number of subjects: 155
Study 30307122 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day STT (rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 7 days)
Number of subjects: 364
Study 30307122 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day STT with bismuth (rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, bismuth subcitrate 240 mg twice daily for 7 days)
Number of subjects: 364
Study 30307122 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day STT (rabeprazole 20 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 14 days)
Number of subjects: 364
Study 25604851 — intervention group
Group type: EXPERIMENTAL
Intervention: mDCF regimen (docetaxel 60 mg/m² on day 1, cisplatin 60 mg/m² on day 1, fluorouracil 600 mg/m²/day on days 1-5)
Number of subjects: 243
Study 25604851 — intervention group
Group type: COMPARATOR
Intervention: CF regimen (cisplatin 75 mg/m² on day 1, fluorouracil 600 mg/m²/day on days 1-5)
Number of subjects: 243
Study 25604851 — intervention group
Group type: EXPERIMENTAL
Intervention: mDCF regimen
Number of subjects: 243
Study 25604851 — intervention group
Group type: COMPARATOR
Intervention: CF regimen
Number of subjects: 243
Study 25348033 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 200 to 400 mg per day
Number of subjects: 510
Study 25348033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study 21910711 — intervention group
Group type: EXPERIMENTAL
Intervention: BF-200 ALA
Number of subjects: 600
Study 21910711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 21910711 — intervention group
Group type: COMPARATOR
Intervention: MAL cream
Number of subjects: 600
Study 19748251 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate (5MTHF)
Number of subjects: 22
Study 19748251 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 22
Study 18459010 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/day for the first 2 years and 10 mg/day thereafter)
Number of subjects: 2785
Study 18459010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2785
Study 15925438 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasonography
Number of subjects: 110
Study 15925438 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 110
Study 12473087 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (cholinesterase inhibitor)
Number of subjects: 0
Study 12473087 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study 10630045 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0
Study 10630045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 0
Study 10630045 — intervention group
Group type: COMPARATOR
Intervention: No drug (Control)
Number of subjects: 0
Study 8550722 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversational turn-taking
Number of subjects: 14
Study 8550722 — intervention group
Group type: COMPARATOR
Intervention: Random responsiveness
Number of subjects: 14
Study 1960558 — intervention group
Group type: EXPERIMENTAL
Intervention: DAVTH (mitolactol, doxorubicin, vincristine, tamoxifen, fluoxymesterone)
Number of subjects: 501
Study 1960558 — intervention group
Group type: EXPERIMENTAL
Intervention: DAVTH
Number of subjects: 501
Study 1960558 — intervention group
Group type: COMPARATOR
Intervention: Ineligible patients
Number of subjects: 501
Study 6758494 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple
Number of subjects: 0
Study 6758494 — intervention group
Group type: EXPERIMENTAL
Intervention: Banana
Number of subjects: 0
Study 6758494 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange
Number of subjects: 0
Study 6758494 — intervention group
Group type: COMPARATOR
Intervention: Pure glucose
Number of subjects: 0
Study 30264259 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching for disease management from Bupa Health Dialog
Number of subjects: 44418
Study 30264259 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 44418
Study 28933133 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve mobilization exercises
Number of subjects: 12
Study 28933133 — intervention group
Group type: COMPARATOR
Intervention: Gentle joint mobilization exercises
Number of subjects: 12
Study 25560423 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive‐pressure ventilation
Number of subjects: 108
Study 25560423 — intervention group
Group type: COMPARATOR
Intervention: Inhaled oxygen
Number of subjects: 108
Study 25082117 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine as an adjunct to lithium
Number of subjects: 74
Study 25082117 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine as an adjunct to lithium
Number of subjects: 74
Study 22993265 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral tDCS over SM1
Number of subjects: 12
Study 22993265 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral tDCS over SM1
Number of subjects: 12
Study 22993265 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study 19545977 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 25
Study 19545977 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 25
Study 18158674 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive lecture
Number of subjects: 0
Study 18158674 — intervention group
Group type: COMPARATOR
Intervention: Game based on charades
Number of subjects: 0
Study 14748765 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/day)
Number of subjects: 800
Study 14748765 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (oral 17beta‐estradiol 1 or 2 mg/day, plus cyclic dydrogesterone 10 mg)
Number of subjects: 800
Study 14748765 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of atorvastatin and HRT
Number of subjects: 800
Study 14748765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 11231376 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium modeling
Number of subjects: 10
Study 11231376 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool temperature dialysis
Number of subjects: 10
Study 11231376 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium dialysate
Number of subjects: 10
Study 11231376 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated ultrafiltration followed by isovolemic dialysis
Number of subjects: 10
Study 11231376 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysis
Number of subjects: 10
Study 9893768 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg salbutamol
Number of subjects: 100
Study 9893768 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms salmeterol
Number of subjects: 100
Study 9893768 — intervention group
Group type: COMPARATOR
Intervention: salbutamol
Number of subjects: 100
Study 8008027 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta carotene (25 mg daily)
Number of subjects: 864
Study 8008027 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins C (1 g daily) and E (400 mg daily)
Number of subjects: 864
Study 8008027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 864
Study 8008027 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta carotene plus vitamins C and E
Number of subjects: 864
Study 2905147 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 15 mg
Number of subjects: 90
Study 2905147 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral temazepam 20 mg
Number of subjects: 90
Study 2905147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90